Pernix Therapeutics (NASDAQ: PTX) and Celsius (NASDAQ:CELH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.
This table compares Pernix Therapeutics and Celsius’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
16.4% of Pernix Therapeutics shares are owned by institutional investors. Comparatively, 6.2% of Celsius shares are owned by institutional investors. 1.4% of Pernix Therapeutics shares are owned by company insiders. Comparatively, 49.0% of Celsius shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Pernix Therapeutics and Celsius, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celsius has a consensus price target of $7.50, suggesting a potential upside of 49.70%. Given Celsius’ higher probable upside, analysts clearly believe Celsius is more favorable than Pernix Therapeutics.
Earnings and Valuation
This table compares Pernix Therapeutics and Celsius’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pernix Therapeutics||$140.86 million||0.19||-$169.59 million||($13.62)||-0.16|
|Celsius||$22.76 million||10.06||-$3.06 million||($0.09)||-55.67|
Celsius has lower revenue, but higher earnings than Pernix Therapeutics. Celsius is trading at a lower price-to-earnings ratio than Pernix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Pernix Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Celsius has a beta of -0.71, meaning that its stock price is 171% less volatile than the S&P 500.
Celsius beats Pernix Therapeutics on 8 of the 13 factors compared between the two stocks.
About Pernix Therapeutics
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.
Celsius Holdings, Inc. is engaged in the development, marketing, sale and distribution of functional calorie-burning fitness beverages under the Celsius brand name. The Company’s product range includes Sparkling Grape Rush, Sparkling Watermelon, Sparkling Orange, Sparkling Wild Berry, Sparkling Cola, Raspberry Acai Green Tea, Peach Mango Green Tea, Flo Fusion Orange and Flo Fusion Berry. The Company’s products are sweetened with sucralose, which is suitable for consumers whose sugar intake is restricted. The Company’s Celsius brand uses ingredients and supplements, such as green tea (EGCG), ginger, calcium, chromium, B vitamins and vitamin C. The Company outsources the manufacturing process to third-party co-packers. It provides co-packers with flavors, ingredient blends, cans and other raw materials for its beverages purchased by it from various suppliers. It sells Celsius brand across retail segments, which include supermarkets and convenience stores.
Receive News & Ratings for Pernix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.